Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|November 4, 2025
8 Cardiology Headlines You Missed in October 2025
Author(s)Ryan Livingston
Fact checked by: Tim Smith
Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.
Advertisement
Advertisement
Cardiology has expanded exponentially in October 2025, between critical new research on GLP-1 receptor agonists and key new approvals from the
Related to this article
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Advertisement
Advertisement